The Federal Circuit affirmed the first covered business method patent review final written decision under the AIA, holding that the PTAB correctly invalidated Versata’s pricing patent under Section 101 and that CBM eligibility determinations are reviewable on appeal — establishing the Federal
An en banc Federal Circuit overruled its prior ‘strong presumption’ that claim terms without the word ‘means’ are not means-plus-function limitations, holding that terms like ‘module’ that claim a function without reciting sufficient structure are subject to Secti
The Federal Circuit held that Sequenom’s patent on detecting paternally inherited cell-free fetal DNA (cffDNA) in maternal blood for non-invasive prenatal diagnosis was patent-ineligible under § 101 — finding the claims directed to a natural phenomenon (cffDNA’s presence in maternal bloo
The Federal Circuit affirmed the bulk of Apple’s massive patent verdict against Samsung — including design patent damages calculated on Samsung’s entire smartphone profits rather than just infringing components — a ruling later reversed by the Supreme Court in a landmark decision on what
The Federal Circuit affirmed infringement findings in a spinal implant patent case but remanded on damages, holding that lost profits are limited to products the patentee itself sells and that convoyed sales damages require a functional relationship between the patented and unpatented products — sig
In the first Federal Circuit decision reviewing an inter partes review (IPR) final written decision, the court affirmed the PTAB’s use of the ‘broadest reasonable interpretation’ claim construction standard in IPR proceedings — a ruling that set the rules for thousands of subsequen
The Federal Circuit affirmed that document-scanning and data-recognition patents are invalid under Section 101 as directed to long-practiced abstract ideas — and notably held that Section 101 invalidity can be decided at the motion to dismiss stage, before claim construction, establishing an early-e
The Federal Circuit held that Myriad’s claims to methods of comparing or analyzing BRCA gene sequences were patent-ineligible under § 101 as directed to abstract mental processes — applying the Supreme Court’s Mayo framework to diagnostic comparison claims on remand from AMP v. Myriad, w
The Federal Circuit held that exporting a single ‘main’ or ‘essential’ component of a patented multi-component product from the U.S. can constitute infringement under Section 271(f)(1) — a ruling the Supreme Court unanimously reversed in 2017, holding that a single component
The Federal Circuit held that DDR Holdings’ patent on a method for retaining website visitors by displaying third-party products within the host website’s visual framework — rather than redirecting visitors to the third-party’s site — was patent-eligible under Alice because the cla